New multi-stakeholder collaboration will drive dialogue on specificities of clinical standards for medical technology
The European Forum for Good Clinical Practice (EFGCP) and MedTech Europe, the alliance of European medical technology industry associations, today announce the establishment of a joint Medical Technology. Working Party within EFGCP aimed at addressing ethical and quality issues when setting standards for clinical evaluation in the medical technology sector.
Setting effective ethical and quality clinical standards for medical technology is critical to ensuring that patients have access to safe and effective treatment. The joint EFGCP-MedTech Europe “Medical Technology Working Party” will seek to involve stakeholders in a dialogue on making sure these standards are broadly accepted and reliably introduced in the rapidly developing, diverse medical technology landscape.
“Historically, the clinical development debate has focused on pharmaceuticals,” said EFGCP Chair Ingrid Klingmann, “but it’s important that we have a deeper conversation about issues that need to be considered when setting standards for the medical technology sector.”
The working party hopes to attract a broad group of expert stakeholders including patient advocates, physician groups, academics, ethics committees, competent authorities and medtech and pharma industry representatives to collect views on good clinical practice, quality and ethical issues as they pertain to medical technology and provide recommendations to policy-makers. MedTech Europe CEO Serge Bernasconi said: “There’s a growing understanding in the healthcare policy arena that we can’t just copy and paste the pharmaceutical approach to clinical standards into EU legislation on medical devices and in vitro diagnostics. Only with a vibrant dialogue can we figure out which direction is right for medical technology and above all, for the patient.”
The working group will initially organise a joint workshop on Mitigating Risks in the Lifecycle of Medical Devices: Options and Challenges in the Medical Device Legislation. The workshop, to be held on 4 December in Brussels, will bring together patients, national competent authorities, ethics committees, lab technicians, healthcare professionals, industry representatives and European regulatory authorities with the aim of finding consensus on key topics of interest and potential policy recommendations.
There will be a separate discussion specifically on in vitro diagnostics and particular considerations related to the proposed IVD Regulation, with the view to organising a high-level, multi-stakeholderroundtable and assess the key concerns.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.